Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats

Background: Chymase generates angiotensin II (ANG II) independently of angiotensin-converting enzyme in tissues and it contributes to vascular remodeling and development of hypertension, however the exact mechanism of its action is unclear. Methods: Hence, the effects of chymase inhibition were exam...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Malwina M. Roszkowska-Chojecka [verfasserIn] Iwona Baranowska [verfasserIn] Olga Gawrys [verfasserIn] Janusz Sadowski [verfasserIn] Agnieszka Walkowska [verfasserIn] Malgorzata Kalisz [verfasserIn] Anna Litwiniuk [verfasserIn] Elzbieta Kompanowska-Jezierska [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	chymase chymostatin hypertension renin-angiotensin system angiotensin ii spontaneously hypertensive rats renal blood flow

Übergeordnetes Werk:	In: Clinical and Experimental Hypertension - Taylor & Francis Group, 2023, 43(2021), 5, Seite 392-401
Übergeordnetes Werk:	volume:43 ; year:2021 ; number:5 ; pages:392-401

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.1080/10641963.2021.1890762

Katalog-ID:	DOAJ099473720

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ099473720
003	DE-627
005	20240414034803.0
007	cr uuu---uuuuu
008	240414s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1080/10641963.2021.1890762 \|2 doi
035			\|a (DE-627)DOAJ099473720
035			\|a (DE-599)DOAJfc2203001dc649d7a2ed576dc376bf11
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC666-701
100	0		\|a Malwina M. Roszkowska-Chojecka \|e verfasserin \|4 aut
245	1	0	\|a Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background: Chymase generates angiotensin II (ANG II) independently of angiotensin-converting enzyme in tissues and it contributes to vascular remodeling and development of hypertension, however the exact mechanism of its action is unclear. Methods: Hence, the effects of chymase inhibition were examined in anesthetized spontaneously hypertensive rats (SHR) in two stages of the disease development, ie. pre-hypertensive (SHR7) and with established hypertension (SHR16). Chymostatin, a commercial chymase inhibitor, was infused intravenously alone or in subsequent groups co-infused with captopril. Results: Mean blood pressure (MBP), total renal blood flow (RBF) and ANG II content (plasma and tissues) were measured. In SHR16 chymase blockade significantly decreased MBP (−6%) and plasma (−38%), kidney (−71%) and heart (−52%) ANG II levels. In SHR7 chymostatin did not influence MBP or RBF, but significantly decreased heart ANG II level. Conclusion: Jointly, functional studies and ANG II determinations support the evidence that in SHR chymase can raise plasma ANG II and contribute to blood pressure elevation. We propose that addition of chymase blockade to ACE inhibition could be a promising approach in the treatment of hypertensive patients resistant to therapy with ACE-inhibitors alone.
650		4	\|a chymase
650		4	\|a chymostatin
650		4	\|a hypertension
650		4	\|a renin-angiotensin system
650		4	\|a angiotensin ii
650		4	\|a spontaneously hypertensive rats
650		4	\|a renal blood flow
653		0	\|a Diseases of the circulatory (Cardiovascular) system
700	0		\|a Iwona Baranowska \|e verfasserin \|4 aut
700	0		\|a Olga Gawrys \|e verfasserin \|4 aut
700	0		\|a Janusz Sadowski \|e verfasserin \|4 aut
700	0		\|a Agnieszka Walkowska \|e verfasserin \|4 aut
700	0		\|a Malgorzata Kalisz \|e verfasserin \|4 aut
700	0		\|a Anna Litwiniuk \|e verfasserin \|4 aut
700	0		\|a Elzbieta Kompanowska-Jezierska \|e verfasserin \|4 aut
773	0	8	\|i In \|t Clinical and Experimental Hypertension \|d Taylor & Francis Group, 2023 \|g 43(2021), 5, Seite 392-401 \|w (DE-627)323606504 \|w (DE-600)2026245-0 \|x 15256006 \|7 nnns
773	1	8	\|g volume:43 \|g year:2021 \|g number:5 \|g pages:392-401
856	4	0	\|u https://doi.org/10.1080/10641963.2021.1890762 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/fc2203001dc649d7a2ed576dc376bf11 \|z kostenfrei
856	4	0	\|u http://dx.doi.org/10.1080/10641963.2021.1890762 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1064-1963 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1525-6006 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_206
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4338
951			\|a AR
952			\|d 43 \|j 2021 \|e 5 \|h 392-401

Indexfelder

author_variant	m m r c mmrc i b ib o g og j s js a w aw m k mk a l al e k j ekj
matchkey_str	article:15256006:2021----::oefhmsibodrsueotopamadisenitniirnlamdnmcadxrto
hierarchy_sort_str	2021
callnumber-subject-code	RC
publishDate	2021
allfields	10.1080/10641963.2021.1890762 doi (DE-627)DOAJ099473720 (DE-599)DOAJfc2203001dc649d7a2ed576dc376bf11 DE-627 ger DE-627 rakwb eng RC666-701 Malwina M. Roszkowska-Chojecka verfasserin aut Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Chymase generates angiotensin II (ANG II) independently of angiotensin-converting enzyme in tissues and it contributes to vascular remodeling and development of hypertension, however the exact mechanism of its action is unclear. Methods: Hence, the effects of chymase inhibition were examined in anesthetized spontaneously hypertensive rats (SHR) in two stages of the disease development, ie. pre-hypertensive (SHR7) and with established hypertension (SHR16). Chymostatin, a commercial chymase inhibitor, was infused intravenously alone or in subsequent groups co-infused with captopril. Results: Mean blood pressure (MBP), total renal blood flow (RBF) and ANG II content (plasma and tissues) were measured. In SHR16 chymase blockade significantly decreased MBP (−6%) and plasma (−38%), kidney (−71%) and heart (−52%) ANG II levels. In SHR7 chymostatin did not influence MBP or RBF, but significantly decreased heart ANG II level. Conclusion: Jointly, functional studies and ANG II determinations support the evidence that in SHR chymase can raise plasma ANG II and contribute to blood pressure elevation. We propose that addition of chymase blockade to ACE inhibition could be a promising approach in the treatment of hypertensive patients resistant to therapy with ACE-inhibitors alone. chymase chymostatin hypertension renin-angiotensin system angiotensin ii spontaneously hypertensive rats renal blood flow Diseases of the circulatory (Cardiovascular) system Iwona Baranowska verfasserin aut Olga Gawrys verfasserin aut Janusz Sadowski verfasserin aut Agnieszka Walkowska verfasserin aut Malgorzata Kalisz verfasserin aut Anna Litwiniuk verfasserin aut Elzbieta Kompanowska-Jezierska verfasserin aut In Clinical and Experimental Hypertension Taylor & Francis Group, 2023 43(2021), 5, Seite 392-401 (DE-627)323606504 (DE-600)2026245-0 15256006 nnns volume:43 year:2021 number:5 pages:392-401 https://doi.org/10.1080/10641963.2021.1890762 kostenfrei https://doaj.org/article/fc2203001dc649d7a2ed576dc376bf11 kostenfrei http://dx.doi.org/10.1080/10641963.2021.1890762 kostenfrei https://doaj.org/toc/1064-1963 Journal toc kostenfrei https://doaj.org/toc/1525-6006 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_206 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4305 GBV_ILN_4338 AR 43 2021 5 392-401
spelling	10.1080/10641963.2021.1890762 doi (DE-627)DOAJ099473720 (DE-599)DOAJfc2203001dc649d7a2ed576dc376bf11 DE-627 ger DE-627 rakwb eng RC666-701 Malwina M. Roszkowska-Chojecka verfasserin aut Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Chymase generates angiotensin II (ANG II) independently of angiotensin-converting enzyme in tissues and it contributes to vascular remodeling and development of hypertension, however the exact mechanism of its action is unclear. Methods: Hence, the effects of chymase inhibition were examined in anesthetized spontaneously hypertensive rats (SHR) in two stages of the disease development, ie. pre-hypertensive (SHR7) and with established hypertension (SHR16). Chymostatin, a commercial chymase inhibitor, was infused intravenously alone or in subsequent groups co-infused with captopril. Results: Mean blood pressure (MBP), total renal blood flow (RBF) and ANG II content (plasma and tissues) were measured. In SHR16 chymase blockade significantly decreased MBP (−6%) and plasma (−38%), kidney (−71%) and heart (−52%) ANG II levels. In SHR7 chymostatin did not influence MBP or RBF, but significantly decreased heart ANG II level. Conclusion: Jointly, functional studies and ANG II determinations support the evidence that in SHR chymase can raise plasma ANG II and contribute to blood pressure elevation. We propose that addition of chymase blockade to ACE inhibition could be a promising approach in the treatment of hypertensive patients resistant to therapy with ACE-inhibitors alone. chymase chymostatin hypertension renin-angiotensin system angiotensin ii spontaneously hypertensive rats renal blood flow Diseases of the circulatory (Cardiovascular) system Iwona Baranowska verfasserin aut Olga Gawrys verfasserin aut Janusz Sadowski verfasserin aut Agnieszka Walkowska verfasserin aut Malgorzata Kalisz verfasserin aut Anna Litwiniuk verfasserin aut Elzbieta Kompanowska-Jezierska verfasserin aut In Clinical and Experimental Hypertension Taylor & Francis Group, 2023 43(2021), 5, Seite 392-401 (DE-627)323606504 (DE-600)2026245-0 15256006 nnns volume:43 year:2021 number:5 pages:392-401 https://doi.org/10.1080/10641963.2021.1890762 kostenfrei https://doaj.org/article/fc2203001dc649d7a2ed576dc376bf11 kostenfrei http://dx.doi.org/10.1080/10641963.2021.1890762 kostenfrei https://doaj.org/toc/1064-1963 Journal toc kostenfrei https://doaj.org/toc/1525-6006 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_206 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4305 GBV_ILN_4338 AR 43 2021 5 392-401
allfields_unstemmed	10.1080/10641963.2021.1890762 doi (DE-627)DOAJ099473720 (DE-599)DOAJfc2203001dc649d7a2ed576dc376bf11 DE-627 ger DE-627 rakwb eng RC666-701 Malwina M. Roszkowska-Chojecka verfasserin aut Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Chymase generates angiotensin II (ANG II) independently of angiotensin-converting enzyme in tissues and it contributes to vascular remodeling and development of hypertension, however the exact mechanism of its action is unclear. Methods: Hence, the effects of chymase inhibition were examined in anesthetized spontaneously hypertensive rats (SHR) in two stages of the disease development, ie. pre-hypertensive (SHR7) and with established hypertension (SHR16). Chymostatin, a commercial chymase inhibitor, was infused intravenously alone or in subsequent groups co-infused with captopril. Results: Mean blood pressure (MBP), total renal blood flow (RBF) and ANG II content (plasma and tissues) were measured. In SHR16 chymase blockade significantly decreased MBP (−6%) and plasma (−38%), kidney (−71%) and heart (−52%) ANG II levels. In SHR7 chymostatin did not influence MBP or RBF, but significantly decreased heart ANG II level. Conclusion: Jointly, functional studies and ANG II determinations support the evidence that in SHR chymase can raise plasma ANG II and contribute to blood pressure elevation. We propose that addition of chymase blockade to ACE inhibition could be a promising approach in the treatment of hypertensive patients resistant to therapy with ACE-inhibitors alone. chymase chymostatin hypertension renin-angiotensin system angiotensin ii spontaneously hypertensive rats renal blood flow Diseases of the circulatory (Cardiovascular) system Iwona Baranowska verfasserin aut Olga Gawrys verfasserin aut Janusz Sadowski verfasserin aut Agnieszka Walkowska verfasserin aut Malgorzata Kalisz verfasserin aut Anna Litwiniuk verfasserin aut Elzbieta Kompanowska-Jezierska verfasserin aut In Clinical and Experimental Hypertension Taylor & Francis Group, 2023 43(2021), 5, Seite 392-401 (DE-627)323606504 (DE-600)2026245-0 15256006 nnns volume:43 year:2021 number:5 pages:392-401 https://doi.org/10.1080/10641963.2021.1890762 kostenfrei https://doaj.org/article/fc2203001dc649d7a2ed576dc376bf11 kostenfrei http://dx.doi.org/10.1080/10641963.2021.1890762 kostenfrei https://doaj.org/toc/1064-1963 Journal toc kostenfrei https://doaj.org/toc/1525-6006 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_206 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4305 GBV_ILN_4338 AR 43 2021 5 392-401
allfieldsGer	10.1080/10641963.2021.1890762 doi (DE-627)DOAJ099473720 (DE-599)DOAJfc2203001dc649d7a2ed576dc376bf11 DE-627 ger DE-627 rakwb eng RC666-701 Malwina M. Roszkowska-Chojecka verfasserin aut Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Chymase generates angiotensin II (ANG II) independently of angiotensin-converting enzyme in tissues and it contributes to vascular remodeling and development of hypertension, however the exact mechanism of its action is unclear. Methods: Hence, the effects of chymase inhibition were examined in anesthetized spontaneously hypertensive rats (SHR) in two stages of the disease development, ie. pre-hypertensive (SHR7) and with established hypertension (SHR16). Chymostatin, a commercial chymase inhibitor, was infused intravenously alone or in subsequent groups co-infused with captopril. Results: Mean blood pressure (MBP), total renal blood flow (RBF) and ANG II content (plasma and tissues) were measured. In SHR16 chymase blockade significantly decreased MBP (−6%) and plasma (−38%), kidney (−71%) and heart (−52%) ANG II levels. In SHR7 chymostatin did not influence MBP or RBF, but significantly decreased heart ANG II level. Conclusion: Jointly, functional studies and ANG II determinations support the evidence that in SHR chymase can raise plasma ANG II and contribute to blood pressure elevation. We propose that addition of chymase blockade to ACE inhibition could be a promising approach in the treatment of hypertensive patients resistant to therapy with ACE-inhibitors alone. chymase chymostatin hypertension renin-angiotensin system angiotensin ii spontaneously hypertensive rats renal blood flow Diseases of the circulatory (Cardiovascular) system Iwona Baranowska verfasserin aut Olga Gawrys verfasserin aut Janusz Sadowski verfasserin aut Agnieszka Walkowska verfasserin aut Malgorzata Kalisz verfasserin aut Anna Litwiniuk verfasserin aut Elzbieta Kompanowska-Jezierska verfasserin aut In Clinical and Experimental Hypertension Taylor & Francis Group, 2023 43(2021), 5, Seite 392-401 (DE-627)323606504 (DE-600)2026245-0 15256006 nnns volume:43 year:2021 number:5 pages:392-401 https://doi.org/10.1080/10641963.2021.1890762 kostenfrei https://doaj.org/article/fc2203001dc649d7a2ed576dc376bf11 kostenfrei http://dx.doi.org/10.1080/10641963.2021.1890762 kostenfrei https://doaj.org/toc/1064-1963 Journal toc kostenfrei https://doaj.org/toc/1525-6006 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_206 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4305 GBV_ILN_4338 AR 43 2021 5 392-401
allfieldsSound	10.1080/10641963.2021.1890762 doi (DE-627)DOAJ099473720 (DE-599)DOAJfc2203001dc649d7a2ed576dc376bf11 DE-627 ger DE-627 rakwb eng RC666-701 Malwina M. Roszkowska-Chojecka verfasserin aut Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Chymase generates angiotensin II (ANG II) independently of angiotensin-converting enzyme in tissues and it contributes to vascular remodeling and development of hypertension, however the exact mechanism of its action is unclear. Methods: Hence, the effects of chymase inhibition were examined in anesthetized spontaneously hypertensive rats (SHR) in two stages of the disease development, ie. pre-hypertensive (SHR7) and with established hypertension (SHR16). Chymostatin, a commercial chymase inhibitor, was infused intravenously alone or in subsequent groups co-infused with captopril. Results: Mean blood pressure (MBP), total renal blood flow (RBF) and ANG II content (plasma and tissues) were measured. In SHR16 chymase blockade significantly decreased MBP (−6%) and plasma (−38%), kidney (−71%) and heart (−52%) ANG II levels. In SHR7 chymostatin did not influence MBP or RBF, but significantly decreased heart ANG II level. Conclusion: Jointly, functional studies and ANG II determinations support the evidence that in SHR chymase can raise plasma ANG II and contribute to blood pressure elevation. We propose that addition of chymase blockade to ACE inhibition could be a promising approach in the treatment of hypertensive patients resistant to therapy with ACE-inhibitors alone. chymase chymostatin hypertension renin-angiotensin system angiotensin ii spontaneously hypertensive rats renal blood flow Diseases of the circulatory (Cardiovascular) system Iwona Baranowska verfasserin aut Olga Gawrys verfasserin aut Janusz Sadowski verfasserin aut Agnieszka Walkowska verfasserin aut Malgorzata Kalisz verfasserin aut Anna Litwiniuk verfasserin aut Elzbieta Kompanowska-Jezierska verfasserin aut In Clinical and Experimental Hypertension Taylor & Francis Group, 2023 43(2021), 5, Seite 392-401 (DE-627)323606504 (DE-600)2026245-0 15256006 nnns volume:43 year:2021 number:5 pages:392-401 https://doi.org/10.1080/10641963.2021.1890762 kostenfrei https://doaj.org/article/fc2203001dc649d7a2ed576dc376bf11 kostenfrei http://dx.doi.org/10.1080/10641963.2021.1890762 kostenfrei https://doaj.org/toc/1064-1963 Journal toc kostenfrei https://doaj.org/toc/1525-6006 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_206 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4305 GBV_ILN_4338 AR 43 2021 5 392-401
language	English
source	In Clinical and Experimental Hypertension 43(2021), 5, Seite 392-401 volume:43 year:2021 number:5 pages:392-401
sourceStr	In Clinical and Experimental Hypertension 43(2021), 5, Seite 392-401 volume:43 year:2021 number:5 pages:392-401
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	chymase chymostatin hypertension renin-angiotensin system angiotensin ii spontaneously hypertensive rats renal blood flow Diseases of the circulatory (Cardiovascular) system
isfreeaccess_bool	true
container_title	Clinical and Experimental Hypertension
authorswithroles_txt_mv	Malwina M. Roszkowska-Chojecka @@aut@@ Iwona Baranowska @@aut@@ Olga Gawrys @@aut@@ Janusz Sadowski @@aut@@ Agnieszka Walkowska @@aut@@ Malgorzata Kalisz @@aut@@ Anna Litwiniuk @@aut@@ Elzbieta Kompanowska-Jezierska @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	323606504
id	DOAJ099473720
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ099473720</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414034803.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1080/10641963.2021.1890762</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ099473720</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJfc2203001dc649d7a2ed576dc376bf11</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Malwina M. Roszkowska-Chojecka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Chymase generates angiotensin II (ANG II) independently of angiotensin-converting enzyme in tissues and it contributes to vascular remodeling and development of hypertension, however the exact mechanism of its action is unclear. Methods: Hence, the effects of chymase inhibition were examined in anesthetized spontaneously hypertensive rats (SHR) in two stages of the disease development, ie. pre-hypertensive (SHR7) and with established hypertension (SHR16). Chymostatin, a commercial chymase inhibitor, was infused intravenously alone or in subsequent groups co-infused with captopril. Results: Mean blood pressure (MBP), total renal blood flow (RBF) and ANG II content (plasma and tissues) were measured. In SHR16 chymase blockade significantly decreased MBP (−6%) and plasma (−38%), kidney (−71%) and heart (−52%) ANG II levels. In SHR7 chymostatin did not influence MBP or RBF, but significantly decreased heart ANG II level. Conclusion: Jointly, functional studies and ANG II determinations support the evidence that in SHR chymase can raise plasma ANG II and contribute to blood pressure elevation. We propose that addition of chymase blockade to ACE inhibition could be a promising approach in the treatment of hypertensive patients resistant to therapy with ACE-inhibitors alone.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chymase</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chymostatin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypertension</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">renin-angiotensin system</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">angiotensin ii</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">spontaneously hypertensive rats</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">renal blood flow</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Iwona Baranowska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Olga Gawrys</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Janusz Sadowski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Agnieszka Walkowska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Malgorzata Kalisz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Litwiniuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elzbieta Kompanowska-Jezierska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Clinical and Experimental Hypertension</subfield><subfield code="d">Taylor & Francis Group, 2023</subfield><subfield code="g">43(2021), 5, Seite 392-401</subfield><subfield code="w">(DE-627)323606504</subfield><subfield code="w">(DE-600)2026245-0</subfield><subfield code="x">15256006</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:43</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:392-401</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1080/10641963.2021.1890762</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/fc2203001dc649d7a2ed576dc376bf11</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1080/10641963.2021.1890762</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1064-1963</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1525-6006</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">43</subfield><subfield code="j">2021</subfield><subfield code="e">5</subfield><subfield code="h">392-401</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Malwina M. Roszkowska-Chojecka
spellingShingle	Malwina M. Roszkowska-Chojecka misc RC666-701 misc chymase misc chymostatin misc hypertension misc renin-angiotensin system misc angiotensin ii misc spontaneously hypertensive rats misc renal blood flow misc Diseases of the circulatory (Cardiovascular) system Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats
authorStr	Malwina M. Roszkowska-Chojecka
ppnlink_with_tag_str_mv	@@773@@(DE-627)323606504
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC666-701
illustrated	Not Illustrated
issn	15256006
topic_title	RC666-701 Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats chymase chymostatin hypertension renin-angiotensin system angiotensin ii spontaneously hypertensive rats renal blood flow
topic	misc RC666-701 misc chymase misc chymostatin misc hypertension misc renin-angiotensin system misc angiotensin ii misc spontaneously hypertensive rats misc renal blood flow misc Diseases of the circulatory (Cardiovascular) system
topic_unstemmed	misc RC666-701 misc chymase misc chymostatin misc hypertension misc renin-angiotensin system misc angiotensin ii misc spontaneously hypertensive rats misc renal blood flow misc Diseases of the circulatory (Cardiovascular) system
topic_browse	misc RC666-701 misc chymase misc chymostatin misc hypertension misc renin-angiotensin system misc angiotensin ii misc spontaneously hypertensive rats misc renal blood flow misc Diseases of the circulatory (Cardiovascular) system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Clinical and Experimental Hypertension
hierarchy_parent_id	323606504
hierarchy_top_title	Clinical and Experimental Hypertension
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)323606504 (DE-600)2026245-0
title	Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats
ctrlnum	(DE-627)DOAJ099473720 (DE-599)DOAJfc2203001dc649d7a2ed576dc376bf11
title_full	Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats
author_sort	Malwina M. Roszkowska-Chojecka
journal	Clinical and Experimental Hypertension
journalStr	Clinical and Experimental Hypertension
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
container_start_page	392
author_browse	Malwina M. Roszkowska-Chojecka Iwona Baranowska Olga Gawrys Janusz Sadowski Agnieszka Walkowska Malgorzata Kalisz Anna Litwiniuk Elzbieta Kompanowska-Jezierska
container_volume	43
class	RC666-701
format_se	Elektronische Aufsätze
author-letter	Malwina M. Roszkowska-Chojecka
doi_str_mv	10.1080/10641963.2021.1890762
author2-role	verfasserin
title_sort	role of chymase in blood pressure control, plasma and tissue angiotensin ii, renal haemodynamics, and excretion in spontaneously hypertensive rats
callnumber	RC666-701
title_auth	Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats
abstract	Background: Chymase generates angiotensin II (ANG II) independently of angiotensin-converting enzyme in tissues and it contributes to vascular remodeling and development of hypertension, however the exact mechanism of its action is unclear. Methods: Hence, the effects of chymase inhibition were examined in anesthetized spontaneously hypertensive rats (SHR) in two stages of the disease development, ie. pre-hypertensive (SHR7) and with established hypertension (SHR16). Chymostatin, a commercial chymase inhibitor, was infused intravenously alone or in subsequent groups co-infused with captopril. Results: Mean blood pressure (MBP), total renal blood flow (RBF) and ANG II content (plasma and tissues) were measured. In SHR16 chymase blockade significantly decreased MBP (−6%) and plasma (−38%), kidney (−71%) and heart (−52%) ANG II levels. In SHR7 chymostatin did not influence MBP or RBF, but significantly decreased heart ANG II level. Conclusion: Jointly, functional studies and ANG II determinations support the evidence that in SHR chymase can raise plasma ANG II and contribute to blood pressure elevation. We propose that addition of chymase blockade to ACE inhibition could be a promising approach in the treatment of hypertensive patients resistant to therapy with ACE-inhibitors alone.
abstractGer	Background: Chymase generates angiotensin II (ANG II) independently of angiotensin-converting enzyme in tissues and it contributes to vascular remodeling and development of hypertension, however the exact mechanism of its action is unclear. Methods: Hence, the effects of chymase inhibition were examined in anesthetized spontaneously hypertensive rats (SHR) in two stages of the disease development, ie. pre-hypertensive (SHR7) and with established hypertension (SHR16). Chymostatin, a commercial chymase inhibitor, was infused intravenously alone or in subsequent groups co-infused with captopril. Results: Mean blood pressure (MBP), total renal blood flow (RBF) and ANG II content (plasma and tissues) were measured. In SHR16 chymase blockade significantly decreased MBP (−6%) and plasma (−38%), kidney (−71%) and heart (−52%) ANG II levels. In SHR7 chymostatin did not influence MBP or RBF, but significantly decreased heart ANG II level. Conclusion: Jointly, functional studies and ANG II determinations support the evidence that in SHR chymase can raise plasma ANG II and contribute to blood pressure elevation. We propose that addition of chymase blockade to ACE inhibition could be a promising approach in the treatment of hypertensive patients resistant to therapy with ACE-inhibitors alone.
abstract_unstemmed	Background: Chymase generates angiotensin II (ANG II) independently of angiotensin-converting enzyme in tissues and it contributes to vascular remodeling and development of hypertension, however the exact mechanism of its action is unclear. Methods: Hence, the effects of chymase inhibition were examined in anesthetized spontaneously hypertensive rats (SHR) in two stages of the disease development, ie. pre-hypertensive (SHR7) and with established hypertension (SHR16). Chymostatin, a commercial chymase inhibitor, was infused intravenously alone or in subsequent groups co-infused with captopril. Results: Mean blood pressure (MBP), total renal blood flow (RBF) and ANG II content (plasma and tissues) were measured. In SHR16 chymase blockade significantly decreased MBP (−6%) and plasma (−38%), kidney (−71%) and heart (−52%) ANG II levels. In SHR7 chymostatin did not influence MBP or RBF, but significantly decreased heart ANG II level. Conclusion: Jointly, functional studies and ANG II determinations support the evidence that in SHR chymase can raise plasma ANG II and contribute to blood pressure elevation. We propose that addition of chymase blockade to ACE inhibition could be a promising approach in the treatment of hypertensive patients resistant to therapy with ACE-inhibitors alone.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_206 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4305 GBV_ILN_4338
container_issue	5
title_short	Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats
url	https://doi.org/10.1080/10641963.2021.1890762 https://doaj.org/article/fc2203001dc649d7a2ed576dc376bf11 http://dx.doi.org/10.1080/10641963.2021.1890762 https://doaj.org/toc/1064-1963 https://doaj.org/toc/1525-6006
remote_bool	true
author2	Iwona Baranowska Olga Gawrys Janusz Sadowski Agnieszka Walkowska Malgorzata Kalisz Anna Litwiniuk Elzbieta Kompanowska-Jezierska
author2Str	Iwona Baranowska Olga Gawrys Janusz Sadowski Agnieszka Walkowska Malgorzata Kalisz Anna Litwiniuk Elzbieta Kompanowska-Jezierska
ppnlink	323606504
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1080/10641963.2021.1890762
callnumber-a	RC666-701
up_date	2024-07-03T22:57:38.184Z
_version_	1803600483513794560
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ099473720</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414034803.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1080/10641963.2021.1890762</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ099473720</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJfc2203001dc649d7a2ed576dc376bf11</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Malwina M. Roszkowska-Chojecka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Chymase generates angiotensin II (ANG II) independently of angiotensin-converting enzyme in tissues and it contributes to vascular remodeling and development of hypertension, however the exact mechanism of its action is unclear. Methods: Hence, the effects of chymase inhibition were examined in anesthetized spontaneously hypertensive rats (SHR) in two stages of the disease development, ie. pre-hypertensive (SHR7) and with established hypertension (SHR16). Chymostatin, a commercial chymase inhibitor, was infused intravenously alone or in subsequent groups co-infused with captopril. Results: Mean blood pressure (MBP), total renal blood flow (RBF) and ANG II content (plasma and tissues) were measured. In SHR16 chymase blockade significantly decreased MBP (−6%) and plasma (−38%), kidney (−71%) and heart (−52%) ANG II levels. In SHR7 chymostatin did not influence MBP or RBF, but significantly decreased heart ANG II level. Conclusion: Jointly, functional studies and ANG II determinations support the evidence that in SHR chymase can raise plasma ANG II and contribute to blood pressure elevation. We propose that addition of chymase blockade to ACE inhibition could be a promising approach in the treatment of hypertensive patients resistant to therapy with ACE-inhibitors alone.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chymase</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chymostatin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypertension</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">renin-angiotensin system</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">angiotensin ii</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">spontaneously hypertensive rats</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">renal blood flow</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Iwona Baranowska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Olga Gawrys</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Janusz Sadowski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Agnieszka Walkowska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Malgorzata Kalisz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Litwiniuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elzbieta Kompanowska-Jezierska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Clinical and Experimental Hypertension</subfield><subfield code="d">Taylor & Francis Group, 2023</subfield><subfield code="g">43(2021), 5, Seite 392-401</subfield><subfield code="w">(DE-627)323606504</subfield><subfield code="w">(DE-600)2026245-0</subfield><subfield code="x">15256006</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:43</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:392-401</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1080/10641963.2021.1890762</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/fc2203001dc649d7a2ed576dc376bf11</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1080/10641963.2021.1890762</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1064-1963</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1525-6006</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">43</subfield><subfield code="j">2021</subfield><subfield code="e">5</subfield><subfield code="h">392-401</subfield></datafield></record></collection>
score	7.4008036

Nicht das Richtige dabei?

Schreiben Sie uns!

Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?